#USA #New York #Securities Fraud #Rosen Law Firm #Capricor Therapeutics

Capricor Investors Offered Chance to Lead Class Action

Investors who purchased shares of Capricor Therapeutics, Inc. (NASDAQ: CAPR) during the specified class period from December 17, 2025, to July 26, 2026, are reminded by the Rosen Law Firm of a significant chance to participate in a class action lawsuit. Collectively, these investors may be entitled to financial compensation due to misleading practices regarding the company’s securities.

Important Deadline

The law firm highlights a critical deadline of September 28, 2026, to file motions to be recognized as lead plaintiffs in this class action. Those who acted in buying Capricor securities during the class period are encouraged to evaluate their options. Joining this class action does not incur upfront costs as the Rosen Law Firm operates on a contingency fee structure.

How to Participate

To participate in this class action, investors can visit the Rosen Law Firm’s dedicated page or directly contact Phillip Kim, Esq. via phone or email. Essential steps have already been outlined for potential class members to signify their intention to be included, which underscores the need for swift action before the deadline passes.

The Case Background

The lawsuit centers on allegations that Capricor made materially false statements and omitted critical details concerning their clinical product, Deramiocel. The firm stated that:

• - Changes to the statistical analysis plan related to Deramiocel were made without FDA approval, which can significantly hamper the validity of their outcomes.
• - This misrepresentation could lead to a failed regulatory approval for Deramiocel, intended for treating Duchenne muscular dystrophy (DMD).

The implications of these allegations suggest that the findings reported about the effectiveness of Deramiocel may not hold. Subsequent market revelations of these discrepancies led to investor dissatisfaction and potential financial damages.

Selecting the Right Counsel

The Rosen Law Firm advises investors on the importance of selecting knowledgeable counsel with a proven track record in securities class action cases. Notably, some firms merely act as intermediaries without substantial experience in litigation. Rosen Law Firm distinguishes itself with a history of successful settlements and recognition in the legal community, emphasizing its capability to advocate effectively for investors’ interests. The firm holds a commendable record, including the largest settlement against a Chinese company and was ranked notably high by ISS Securities Class Action Services.

Conclusion

With potential damages on the line and the chance for compensation available, Capricor Therapeutics investors should act quickly to understand their eligibility for this class action lawsuit. Failure to do so by the September 28 deadline may forfeit the opportunity to receive any compensation that could be a result of the lawsuit. Relevant links and contact information are crucial for investors considering joining this case. The Rosen Law Firm continues to support clients globally, focusing on investor rights and the protection of those impacted by misleading statements in the financial markets.